-
公开(公告)号:US20240337669A1
公开(公告)日:2024-10-10
申请号:US18681772
申请日:2022-08-04
Inventor: Nathan Joseph Alves , Ziqian Zeng
CPC classification number: G01N33/86 , C07K14/75 , C12Q1/37 , G01N33/96 , G01N2333/75 , G01N2333/9726 , G01N2500/04
Abstract: Disclosed are compositions and methods of a microplate-based assay related to the field of thrombosis diagnosis, therapeutic screening, and drug development platforms.
-
公开(公告)号:US12038431B2
公开(公告)日:2024-07-16
申请号:US18054595
申请日:2022-11-11
Applicant: MEDIC LIFE SCIENCES INC.
Inventor: Kyuho Han , Hong-Pyo Lee
CPC classification number: G01N33/5008 , C07K19/00 , C12N15/1037 , G01N33/5011 , G01N33/502 , C07K2319/03 , C07K2319/035 , G01N2500/04
Abstract: The present disclosure provides a high-throughput screening system and method for identification of novel drugs and drug targets. The method enables large-scale analysis of interactions between allogeneic pairs of target cells and immune cells by using an immune-bridge protein, library of guide RNA, and/or 3D tumor model.
-
公开(公告)号:US20240167074A1
公开(公告)日:2024-05-23
申请号:US18549554
申请日:2022-03-08
Applicant: Baylor College of Medicine
Inventor: Thomas F. Westbrook , Kristen Karlin , Calla Olson
CPC classification number: C12Q1/34 , G01N33/5008 , G01N2500/04 , G01N2500/10
Abstract: Embodiments of the disclosure concern identification of suitable inhibitors of components of RNA metabolism, including those involved with splicing, such as RNA helicases. The disclosure includes in vitro screens for small molecule inhibitors that are selective for a group of RNA helicases but that are counter-selective for another group of RNA helicases. In specific embodiments, the disclosure includes a system for inhibitor analysis that includes assay development and optimization that leads to feasible screening of the intended target(s) and continued counter-selection against undesirable targets throughout the process.
-
公开(公告)号:US11929151B2
公开(公告)日:2024-03-12
申请号:US17158940
申请日:2021-01-26
Applicant: Immunocore Limited , Adaptimmune Limited
CPC classification number: G16B35/20 , G01N33/505 , G01N33/6866 , G01N33/6878 , G16B35/00 , G16C20/60 , G01N2333/57 , G01N2333/70539 , G01N2500/04
Abstract: The invention provides a method for predicting whether a binding peptide, which binds to a target peptide presented by a Major Histocompatibility Complex (MHC) and is for administration to a subject, has the potential to cross react with another peptide in the subject in vivo. The method comprises the steps of identifying at least one binding motif in the target peptide to which the binding peptide binds; and searching for peptides that are present in the subject that comprise the at least one binding motif and that are not the target peptide. The presence of one or more such peptides indicates that the binding peptide has the potential to cross react in vivo.
-
公开(公告)号:US11911407B2
公开(公告)日:2024-02-27
申请号:US15955628
申请日:2018-04-17
Inventor: Chris Watson , John Baugh , Mark Ledwidge , Ken McDonald
IPC: A61K31/7064 , A61K31/706 , A61K31/713 , C12Q1/6883 , G01N33/50
CPC classification number: A61K31/7064 , A61K31/706 , A61K31/713 , C12Q1/6883 , G01N33/5023 , C12Q2600/136 , C12Q2600/154 , C12Q2600/158 , G01N2500/02 , G01N2500/04 , G01N2500/10 , G01N2800/325
Abstract: The present invention relates to therapies and therapeutic agents for use in the treatment of cardiomyopathies. In particular, the invention is concerned with, but not limited to therapies and therapeutic agents for use in the treatment of hypertrophic cardiomyopathy. Such therapeutic agents comprise hypomethylating agents.
-
公开(公告)号:US20240058482A1
公开(公告)日:2024-02-22
申请号:US18104037
申请日:2023-01-31
Inventor: Gabriela Chiosis , Nagavarakishore Pillarsetty , Jason S. Lewis , Steven M. Larson , Tony Taldone , Mary L. Alpaugh , Erica M. Gomes-DaGama
IPC: A61K51/04 , A61K31/52 , G01N33/50 , G01N33/574
CPC classification number: A61K51/0459 , A61K31/52 , G01N33/5011 , G01N33/5017 , G01N33/574 , G01N33/57407 , G01N33/57426 , G01N33/5044 , G01N2500/04 , G01N2800/52
Abstract: This invention concerns various methods of using labeled HSP90 inhibitors to improve treatment of cancer patients with HSP90 inhibitors, including ex vivo and in vivo methods for determining whether a tumor will likely respond to therapy with an HSP90 inhibitor.
-
公开(公告)号:US20230406902A1
公开(公告)日:2023-12-21
申请号:US18316893
申请日:2023-05-12
Applicant: BioNTech SE , Tron-Translationale Onkologie an der Universitätsmedizin der Johannes Gutenberg-Universität Mainz , JPT Peptide Technologies GmbH
Inventor: Ugur Sahin , Matin Daneschdar , Hans-Ulrich Schmoldt , Laura-Marie Kring (née Plum) , Markus Fiedler , Ulf Reimer , Karsten Schnatbaum
IPC: C07K14/705 , G01N33/53 , C07K7/64 , A61K38/12 , A61K38/08 , A61K39/00 , G01N33/574
CPC classification number: C07K14/705 , G01N33/5308 , C07K7/64 , A61K38/12 , A61K38/08 , A61K39/0005 , G01N33/57492 , G01N2500/04 , G01N2333/705 , G01N2500/02
Abstract: The present invention provides molecules that mimic antigenic determinants of the integral transmembrane protein claudin 18.2 (CLDN18.2). These molecules compete with CLDN18.2 for binding to a CLDN18.2 binding domain, e.g. a CLDN18.2 binding domain of an antibody, and are capable of detecting antibodies against CLDN18.2. The mimotopes of the invention may be used to generate or inhibit immune responses in animals and preferably humans. Furthermore, they can be used for purposes of detecting agents comprising a CLDN18.2 binding domain in biological samples as well as for purifying agents comprising a CLDN18.2 binding domain.
-
公开(公告)号:US20230375542A1
公开(公告)日:2023-11-23
申请号:US18339347
申请日:2023-06-22
Applicant: Depixus SAS
Inventor: Gordon HAMILTON , Jimmy OUELLET , Zhen WANG , Henning LABUHN
IPC: G01N33/543 , G01N33/53
CPC classification number: G01N33/54373 , G01N33/5308 , G01N33/54326 , G01N2500/04
Abstract: Disclosed herein are methods of screening candidate binding compounds to a plurality of target nucleic acids either of the same sequence or of different sequences utilizing a device configured to detect changes in the folding and unfolding force of the target nucleic acid upon binding to various candidate binding compounds. In the presence of a plurality of nucleic acid sequences, the methods described herein also can rapidly determine the specificity of the small molecule or polypeptide to a nucleic acid structure. Also, disclosed herein are methods of measuring binding kinetics of binding compounds to a target nucleic acid using a device configured to detect changes in the folding and unfolding force of the target nucleic acid upon binding to varying concentrations of the candidate binding compound.
-
公开(公告)号:US20230341406A1
公开(公告)日:2023-10-26
申请号:US17965967
申请日:2022-10-14
Applicant: Deutsches Krebsforschungszentrum
Inventor: Tong-Young LEE , Amir ABDOLLAHI , Kashi JAVAHERIAN
IPC: G01N33/574 , A61K38/39 , A61K47/68 , C07K14/78 , C07K14/435
CPC classification number: G01N33/57484 , A61K38/39 , A61K47/6883 , C07K14/78 , C07K14/435 , C07K2319/21 , C07K2319/30 , C07K2319/50 , C07K2319/00 , G01N2500/04 , G01N2500/10
Abstract: The present invention is concerned with a protein oligomer comprising at least two NC-1 monomers of human collagen 18 or fragments of an NC-1 monomer of human collagen 18 for use in the treatment or prevention of an angiogenesis-related disease. The invention further pertains to a fusion protein comprising a NC-1 monomer of human collagen 18 and a Fc domain of an immunoglobulin. The invention also relates to a fusion protein comprising: a) an endostatin peptide or endostatin-derived peptide and b) the RGD motif and/or PHSRN motif of Fibronectin. The invention further relates to a kit comprising the protein oligomer or fusion proteins of the invention.
-
公开(公告)号:US11773165B2
公开(公告)日:2023-10-03
申请号:US17736874
申请日:2022-05-04
Inventor: Ravindra Majeti , Irving L. Weissman
IPC: A61P35/02 , C07K16/28 , C07K16/30 , C12Q1/6886 , G01N33/50 , G01N33/574 , C12N5/00 , C12N5/09 , A61K39/00
CPC classification number: C07K16/2803 , A61P35/02 , C07K16/28 , C07K16/2896 , C07K16/30 , C12N5/0093 , C12N5/0694 , C12Q1/6886 , G01N33/5011 , G01N33/57426 , A61K2039/505 , A61K2039/507 , C07K2317/24 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C12Q2600/112 , C12Q2600/136 , G01N2500/04
Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.
-
-
-
-
-
-
-
-
-